International Assets Investment Management LLC Acquires 71,182 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

International Assets Investment Management LLC increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 527.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 84,682 shares of the company’s stock after purchasing an additional 71,182 shares during the quarter. International Assets Investment Management LLC’s holdings in Recursion Pharmaceuticals were worth $558,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of RXRX. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after buying an additional 6,036 shares during the period. Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the period. San Luis Wealth Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the third quarter valued at approximately $69,000. Finally, Vontobel Holding Ltd. acquired a new position in shares of Recursion Pharmaceuticals in the third quarter valued at approximately $70,000. 89.06% of the stock is owned by institutional investors.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $7.12, for a total value of $81,502.64. Following the transaction, the director now directly owns 7,132,769 shares of the company’s stock, valued at $50,785,315.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total transaction of $81,502.64. Following the transaction, the director now directly owns 7,132,769 shares in the company, valued at approximately $50,785,315.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 171,682 shares of company stock worth $1,107,868 over the last quarter. 15.75% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on RXRX shares. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group reduced their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. KeyCorp reduced their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $6.82 on Wednesday. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.03 and a 12 month high of $15.74. The firm has a fifty day simple moving average of $6.61 and a 200 day simple moving average of $7.64. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -4.21 and a beta of 0.81. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The firm had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business’s revenue was up 30.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.38) EPS. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.